Dabigatran – a case history demonstrating the need for comprehensive approaches to optimize the use of new drugs
暂无分享,去创建一个
A. Haycox | S. Simoens | R. Malmström | L. Gustafsson | M. Bennie | J. Wale | S. Campbell | S. Jan | I. Gutiérrez-Ibarluzea | B. Godman | M. Hoffmann | A. Bucsics | L. McCullagh | K. Garuolienė | H. Herholz | O. Laius | A. Ferrario | M. Władysiuk | Cankat Tulunay | A. Finlayson | Jan Jones | I. Bishop | E. Diògene | Jurij Fürst | M. Gomes | Krystyna Hviding | Marija Kalaba | Christina Kvalheim | Sven-Åke Lööv | Kamila Malinowska | Andrew Martin | K. Paterson | G. Selke | C. Sermet | D. Tomek | L. Voncina | M. van Woerkom | Corrine Zara | Vanda Marković-Peković | Irene Langner | R. Joppi | M. Wilcock | Julie Lonsdale | A. Brzezińska | Jutta Piessnegger | V. Vlahović‐Palčevski | A. Martin | C. Baumgärtel | Anna Bucsics | Saira A. Jan
[1] Rahul Wadke,et al. Atrial fibrillation. , 2022, Disease-a-month : DM.
[2] V. Pengo,et al. Hospitalized patients with atrial fibrillation compared to those included in recent trials on novel oral anticoagulants: a population-based study. , 2013, European journal of internal medicine.
[3] Marsha E Reichman,et al. Dabigatran and postmarketing reports of bleeding. , 2013, The New England journal of medicine.
[4] B. Godman. Health authority perspective on biosimilars , 2013 .
[5] Z. Kmietowicz. GSK backs campaign for disclosure of trial data , 2013, BMJ : British Medical Journal.
[6] J. Dawson,et al. Stop the clots, but at what cost? Pharmacoeconomics of dabigatran etexilate for the prevention of stroke in subjects with atrial fibrillation: a systematic literature review , 2013, Expert review of pharmacoeconomics & outcomes research.
[7] P. Wells,et al. Non‐adherence to new oral anticoagulants: a reason for concern during long‐term anticoagulation? , 2013, Journal of thrombosis and haemostasis : JTH.
[8] L. Gustafsson,et al. A New Reimbursement System for Innovative Pharmaceuticals Combining Value-Based and Free Market Pricing , 2013, Applied Health Economics and Health Policy.
[9] L. Levin,et al. Cost-effectiveness of dabigatran compared with warfarin for patients with atrial fibrillation in Sweden. , 2013, European heart journal.
[10] M. Bennie,et al. Essential to increase the use of generics in Europe to maintain comprehensive health care , 2012 .
[11] M. Bennie,et al. Possible ways to enhance renin-angiotensin prescribing efficiency: Republic of Serbia as a case history? , 2012, Journal of comparative effectiveness research.
[12] L. Gustafsson,et al. Ongoing measures to enhance the efficiency of prescribing of proton pump inhibitors and statins in The Netherlands: influence and future implications. , 2012, Journal of comparative effectiveness research.
[13] L. Gustafsson,et al. Ongoing initiatives in the Republic of Srpska to enhance prescribing efficiency: influence and future directions , 2012, Expert review of pharmacoeconomics & outcomes research.
[14] Donny Wong,et al. The pharmaceutical market for obesity therapies , 2012, Nature Reviews Drug Discovery.
[15] M. Dietrich,et al. Limitations in anti-obesity drug development: the critical role of hunger-promoting neurons , 2012, Nature Reviews Drug Discovery.
[16] J. Finsterer,et al. Concerns about storage and application of dabigatran and rivaroxaban , 2012, European Journal of Clinical Pharmacology.
[17] R. Malmström,et al. Improving the managed entry of new medicines: sharing experiences across Europe , 2012, Expert review of pharmacoeconomics & outcomes research.
[18] M. Civaner. Sale strategies of pharmaceutical companies in a "pharmerging" country: the problems will not improve if the gaps remain. , 2012, Health policy.
[19] A. Bucsics,et al. Discounts and rebates granted to public payers for medicines in European countries , 2012, Southern med review.
[20] M. Bennie,et al. Payers endorse generics to enhance prescribing efficiency: impact and future implications, a case history approach , 2012 .
[21] M. Bennie,et al. What lessons can be learned from the launch of generic clopidogrel , 2012 .
[22] Walavan Sivakumar,et al. Neurosurgical complications of direct thrombin inhibitors--catastrophic hemorrhage after mild traumatic brain injury in a patient receiving dabigatran. , 2012, Journal of neurosurgery.
[23] M. Mello,et al. Pharmaceutical companies' role in state vaccination policymaking: the case of human papillomavirus vaccination. , 2012, American journal of public health.
[24] H. Cate. Monitoring new oral anticoagulants, managing thrombosis, or both? , 2012 .
[25] J. Dogné,et al. Impact of dabigatran on a large panel of routine or specific coagulation assays , 2012, Thrombosis and Haemostasis.
[26] Paul Robinson,et al. Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in UK patients with atrial fibrillation , 2012, Heart.
[27] E. Merriman,et al. Bleeding risk with dabigatran in the frail elderly. , 2012, The New England journal of medicine.
[28] B. Wettermark,et al. European payer initiatives to reduce prescribing costs through use of generics , 2012 .
[29] J. Kaiser. Personalized medicine. New cystic fibrosis drug offers hope, at a price. , 2012, Science.
[30] G. Lip,et al. Dabigatran etexilate for stroke prevention in patients with atrial fibrillation: Resolving uncertainties in routine practice , 2012, Thrombosis and Haemostasis.
[31] Asher Mullard,et al. 2011 FDA drug approvals , 2012, Nature Reviews Drug Discovery.
[32] H. Krumholz,et al. Generic atorvastatin and health care costs. , 2012, The New England journal of medicine.
[33] A. Banerjee,et al. Net clinical benefit of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus no treatment in a ‘real world’ atrial fibrillation population: A modelling analysis based on a nationwide cohort study , 2011, Thrombosis and Haemostasis.
[34] R. Malmström,et al. Prescribing restrictions – a necessary strategy among some European countries to enhance future prescribing efficiency? , 2011 .
[35] S. Yusuf,et al. Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in patients with non‐valvular atrial fibrillation from the RE‐LY trial , 2011, Journal of thrombosis and haemostasis : JTH.
[36] Munir Pirmohamed,et al. Dabigatran etexilate versus warfarin in management of non-valvular atrial fibrillation in UK context: quantitative benefit-harm and economic analyses , 2011, BMJ : British Medical Journal.
[37] M. Toumi,et al. Market access agreements for pharmaceuticals in Europe: diversity of approaches and underlying concepts , 2011, BMC health services research.
[38] K. Kolasa,et al. A review of Health Technology Assessment (HTA) recommendations for drug therapies issued between 2007 and 2009 and their impact on policymaking processes in Poland. , 2011, Health policy.
[39] Karol Sikora,et al. Delivering affordable cancer care in high-income countries. , 2011, The Lancet. Oncology.
[40] M. Mckee,et al. Pharmaceutical lobbying under postcommunism: universal or country-specific methods of securing state drug reimbursement in Poland? , 2011, Health Economics, Policy and Law.
[41] L. Gustafsson,et al. Influence of demand-side measures to enhance renin–angiotensin prescribing efficiency in Europe: implications for the future , 2011, Expert review of pharmacoeconomics & outcomes research.
[42] B. M. Keegan,et al. Natalizumab for multiple sclerosis: a complicated treatment , 2011, The Lancet Neurology.
[43] M. Legrand,et al. The use of dabigatran in elderly patients. , 2011, Archives of internal medicine.
[44] Malcolm Rowland,et al. Bridging the efficacy–effectiveness gap: a regulator's perspective on addressing variability of drug response , 2011, Nature Reviews Drug Discovery.
[45] A. Haycox,et al. European countries with small populations can obtain low prices for drugs: Lithuania as a case history , 2011, Expert review of pharmacoeconomics & outcomes research.
[46] P. Hjemdahl,et al. The 'wise list'- a comprehensive concept to select, communicate and achieve adherence to recommendations of essential drugs in ambulatory care in Stockholm. , 2011, Basic & clinical pharmacology & toxicology.
[47] A. Haycox,et al. Combination of prescribing restrictions and policies to engineer low prices to reduce reimbursement costs , 2011, Expert review of pharmacoeconomics & outcomes research.
[48] K. Facey,et al. What principles should govern the use of managed entry agreements? , 2011, International Journal of Technology Assessment in Health Care.
[49] J. McNeil,et al. Pharmacotherapies for Obesity: Past, Current, and Future Therapies , 2010, Journal of obesity.
[50] B. Wettermark,et al. Comparing policies to enhance prescribing efficiency in Europe through increasing generic utilization: changes seen and global implications , 2010, Expert review of pharmacoeconomics & outcomes research.
[51] B. Wettermark,et al. Policies to Enhance Prescribing Efficiency in Europe: Findings and Future Implications , 2010, Front. Pharmacol..
[52] A. Camm,et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). , 2010, European heart journal.
[53] H. Enlund,et al. Impact of Restricted Reimbursement on the Use of Statins in Finland: A Register-Based Study , 2010, Medical care.
[54] P. Hjemdahl,et al. Forecasting drug utilization and expenditure in a metropolitan health region , 2010, BMC health services research.
[55] S. Rolfe,et al. Controversies of Anticoagulation Reversal in Life-Threatening Bleeds , 2010, Journal of pharmacy practice.
[56] S. Laporte,et al. New oral antithrombotics: a need for laboratory monitoring. For , 2010, Journal of thrombosis and haemostasis : JTH.
[57] Thomas Kahan,et al. Initial effects of a reimbursement restriction to improve the cost-effectiveness of antihypertensive treatment. , 2010, Health policy.
[58] A. Haycox,et al. Initiatives to enhance the quality and efficiency of statin and PPI prescribing in the UK: impact and implications , 2010, Expert review of pharmacoeconomics & outcomes research.
[59] S. Yusuf,et al. Dabigatran versus warfarin in patients with atrial fibrillation. , 2009, The New England journal of medicine.
[60] P. Hjemdahl,et al. [New drug in atrial fibrillation--how does it function in regular health care?]. , 2009, Lakartidningen.
[61] B. Wettermark,et al. Impact of recent reforms in Austria on utilization and expenditure of PPIs and lipid-lowering drugs: implications for the future , 2009, Expert review of pharmacoeconomics & outcomes research.
[62] B. Wettermark,et al. Soft regulations in pharmaceutical policy making , 2009, Applied health economics and health policy.
[63] J. Crippa,et al. The psychiatric side-effects of rimonabant. , 2009, Revista brasileira de psiquiatria.
[64] A. Haycox,et al. Multifaceted national and regional drug reforms and initiatives in ambulatory care in Sweden: global relevance , 2009, Expert review of pharmacoeconomics & outcomes research.
[65] A. Clemens,et al. Pharmacology, Pharmacokinetics, and Pharmacodynamics of Dabigatran Etexilate, an Oral Direct Thrombin Inhibitor , 2009, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.
[66] S. Spinler,et al. Dabigatran Etexilate: An Oral Direct Thrombin Inhibitor for Prophylaxis and Treatment of Thromboembolic Diseases , 2008, Pharmacotherapy.
[67] J. Abraham. Sociology of pharmaceuticals development and regulation: a realist empirical research programme. , 2008, Sociology of health & illness.
[68] A. Haycox,et al. Insight into recent reforms and initiatives in Austria: implications for key stakeholders , 2008, Expert review of pharmacoeconomics & outcomes research.
[69] Paul C Nagle,et al. Characteristics of and trends in the late-stage biopharmaceutical pipeline. , 2008, The American journal of managed care.
[70] Andrew Jack,et al. Balancing Big Pharma’s books , 2008, BMJ : British Medical Journal.
[71] Blair T. Johnson,et al. Initial Severity and Antidepressant Benefits: A Meta-Analysis of Data Submitted to the Food and Drug Administration , 2008, PLoS medicine.
[72] R. Frank,et al. The ongoing regulation of generic drugs. , 2007, The New England journal of medicine.
[73] Bertil Olsson,et al. Outcome parameters for trials in atrial fibrillation: executive summary. , 2007, European heart journal.
[74] J. DiMasi,et al. The cost of biopharmaceutical R&D: is biotech different? , 2007 .
[75] Ludwig Kappos,et al. Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring , 2007, The Lancet Neurology.
[76] P. Rothwell,et al. Population-Based Study of Determinants of Initial Secondary Care Costs of Acute Stroke in the United Kingdom , 2006, Stroke.
[77] M. Shuchman. Delaying generic competition--corporate payoffs and the future of Plavix. , 2006, The New England journal of medicine.
[78] H. Kohli. Scottish Medicines Consortium. , 2005, The National medical journal of India.
[79] C. Lines,et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. , 2005, The New England journal of medicine.
[80] D. Levy,et al. Lifetime Risk for Development of Atrial Fibrillation: The Framingham Heart Study , 2004, Circulation.
[81] J. McMurray,et al. Cost of an emerging epidemic: an economic analysis of atrial fibrillation in the UK , 2004, Heart.
[82] R. Sperling,et al. Selective COX-2 inhibition and cardiovascular effects: a review of the rofecoxib development program. , 2003, American heart journal.
[83] B. Beermann,et al. Evidence b(i)ased medicine—selective reporting from studies sponsored by pharmaceutical industry: review of studies in new drug applications , 2003, BMJ : British Medical Journal.
[84] J. Cleland,et al. Effectiveness versus efficacy: more than a debate over language. , 2003, The Journal of orthopaedic and sports physical therapy.
[85] A. Carlsson. NOBEL LECTURE: A Half-Century of Neurotransmitter Research: Impact on Neurology and Psychiatry , 2001 .
[86] J. McMurray,et al. Population prevalence, incidence, and predictors of atrial fibrillation in the Renfrew/Paisley study , 2001, Heart.
[87] A. Reicin,et al. OP0133 Cardiovascular safety profile of rofecoxib: a meta-analysis , 2001 .
[88] D. Singer,et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. , 2001, JAMA.
[89] Lise,et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. , 2000, The New England journal of medicine.
[90] E. Guthrie,et al. Psychotherapy for patients with complex disorders and chronic symptoms , 2000, British Journal of Psychiatry.
[91] J. Woodcock,et al. The safety of newly approved medicines: do recent market removals mean there is a problem? , 1999, JAMA.
[92] S. Garattini,et al. New drugs for thromboprophylaxis in atrial fibrillation. , 2012, European journal of internal medicine.
[93] B. Wettermark,et al. Update of Recent Reforms in Germany to Enhance the Quality and Efficiency of Prescribing of Proton Pump Inhibitors and Lipid-Lowering Drugs , 2012, PharmacoEconomics.
[94] C. Gandhi. Neurosurgical complications of direct thrombin inhibitors—catastrophic hemorrhage after mild traumatic brain injury in a patient receiving dabigatran , 2012 .
[95] A. Haycox,et al. Recent National and Regional Drug Reforms in Sweden , 2012, PharmacoEconomics.
[96] K. Garuolienė. Pharmaceutical policies and the economic crisis 1 Pharmaceutical policy and the effects of the economic crisis : Lithuania , 2011 .
[97] J. Kohler,et al. The danger of imperfect regulation: OxyContin use in the United States and Canada. , 2011, The International journal of risk & safety in medicine.
[98] Brian Godman,et al. Ongoing pharmaceutical reforms in France: implications for key stakeholder groups. , 2010, Applied health economics and health policy.
[99] Ken Paterson,et al. Einführung neuer Arzneimittel in europäische Gesundheitssysteme , 2010 .
[100] L. Voncina,et al. Croatia: 2009/2010 pharmaceutical pricing and reimbursement reform. , 2010 .
[101] B. Wettermark,et al. Financial incentives linked to self-assessment of prescribing patterns: a new approach for quality improvement of drug prescribing in primary care. , 2009, Quality in primary care.
[102] K. Rathgen,et al. Pharmacokinetics and Pharmacodynamics of the Direct Oral Thrombin Inhibitor Dabigatran in Healthy Elderly Subjects , 2008, Clinical pharmacokinetics.
[103] K. Wells,et al. Treatment research at the crossroads: the scientific interface of clinical trials and effectiveness research. , 1999, The American journal of psychiatry.